CA2262007A1 - Env-glycoprotein vaccine for protection of htlv-i and -ii infection - Google Patents

Env-glycoprotein vaccine for protection of htlv-i and -ii infection Download PDF

Info

Publication number
CA2262007A1
CA2262007A1 CA002262007A CA2262007A CA2262007A1 CA 2262007 A1 CA2262007 A1 CA 2262007A1 CA 002262007 A CA002262007 A CA 002262007A CA 2262007 A CA2262007 A CA 2262007A CA 2262007 A1 CA2262007 A1 CA 2262007A1
Authority
CA
Canada
Prior art keywords
htlv
protein
env
subject
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002262007A
Other languages
English (en)
French (fr)
Inventor
William W. Hall
Hidehiro Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2262007A1 publication Critical patent/CA2262007A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002262007A 1996-07-22 1997-07-22 Env-glycoprotein vaccine for protection of htlv-i and -ii infection Abandoned CA2262007A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68105496A 1996-07-22 1996-07-22
US08/681,054 1996-07-22
US89789897A 1997-07-21 1997-07-21
US08/897,898 1997-07-21
PCT/US1997/012776 WO1998003197A1 (en) 1996-07-22 1997-07-22 Env-glycoprotein vaccine for protection of htlv-i and -ii infection

Publications (1)

Publication Number Publication Date
CA2262007A1 true CA2262007A1 (en) 1998-01-29

Family

ID=27102582

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002262007A Abandoned CA2262007A1 (en) 1996-07-22 1997-07-22 Env-glycoprotein vaccine for protection of htlv-i and -ii infection

Country Status (4)

Country Link
EP (1) EP0942748A4 (de)
JP (1) JP2002513381A (de)
CA (1) CA2262007A1 (de)
WO (1) WO1998003197A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2610265B1 (de) * 2003-05-02 2016-11-16 Centre National de la Recherche Scientifique (C.N.R.S.) Glut-1 als Rezeptor für HTLV-Hüllen und dessen Verwendungen
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
DK2172211T3 (en) 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
WO2010079208A1 (en) 2009-01-09 2010-07-15 Centre National De La Recherche Scientifique New receptor binding ligands, their use in the detection of cells with biological interest

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743678A (en) * 1983-04-27 1988-05-10 President And Fellows Of Harvard College Method and products for detection of human T cell leukemia virus
US5516632A (en) * 1988-02-08 1996-05-14 Duke University Synthetic peptides

Also Published As

Publication number Publication date
JP2002513381A (ja) 2002-05-08
EP0942748A4 (de) 2004-12-08
WO1998003197A1 (en) 1998-01-29
EP0942748A1 (de) 1999-09-22

Similar Documents

Publication Publication Date Title
US5643756A (en) Fusion glycoproteins
US5955342A (en) Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US5580773A (en) Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
Luo et al. Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells
US6544752B1 (en) Anigenically-marked non-infectious retrovirus-like particles
EP0550599B1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
WO1991000904A1 (en) Expression of retrovirus gag protein in eukaryotic cells
EP1038001B1 (de) Konstitutive expression von nicht-infektiöser hiv-ähnlicher teilchen
JP2002533125A (ja) 改変hivenvポリペプチド
EP0577894B1 (de) Entwurf, Konstruktion und Expression von chimärischen Proteinen zur Entwicklung von Impfstoffen und diagnostischen Reagenzien
KR19990044093A (ko) 다수-서브타입 fiv 백신
CA2181590C (en) Peptomers with enhanced immunogenicity
JPH11515006A (ja) ヒト免疫不全ウイルス感染の予防用合成ワクチン
Erturk et al. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection
CA2262007A1 (en) Env-glycoprotein vaccine for protection of htlv-i and -ii infection
WO1994002612A1 (en) Anti-feline immunodeficiency virus (fiv) vaccines
Charbit et al. Immunogenicity and antigenicity of conserved peptides from the envelope of HIV-1 expressed at the surface of recombinant bacteria
WO1994000562A1 (en) A novel human immunodeficiency virus
WO1998003197A9 (en) Env-glycoprotein vaccine for protection of htlv-i and -ii infection
JPH09512561A (ja) ヒト免疫不全ウイルス感染に対する防御用合成ワクチン
US20080267989A1 (en) Hiv Gp-41-Membrane Proximal Region Arrayed On Hepatitis B Surface Antigen Particles as Novel Antigens
US20050025779A1 (en) HIV-1 envelope glycoproteins having unusual disulfide structure
EP0693938B1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
ES2221664T3 (es) Peptidos derivados de gp21 de htlv-i y htlv-ii para uso en diagnostico.
EP0328390B1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20050722